Suggested remit: To appraise the clinical and cost effectiveness of isatuximab in combination with carfilzomib and dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma.
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
 
Status Suspended
Process STA 2018
ID number 1620

Timeline

Key events during the development of the guidance:

Date Update
08 December 2020 Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
02 November 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1620. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that is developing isatuximab has advised NICE that they do not intend to participate in a Technology Appraisal for this topic. In light of this information the Institute will not be progressing with the scoping exercise. Consequently the consultation on the draft scope will now close. Please accept our apologies for any inconvenience this may cause. The topic will progress to Technology Appraisal to then be suspended. If you have any comments or concerns please contact the project manager for this appraisal Michelle Adhemar at michelle.adhemar@nice.org.uk

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance